• United Therapeutics Chairperson, CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 146.03 on May 5, 2026.
• Rothblatt sold 9,500 shares in multiple transactions at prices around USD 567.27 to USD 581.68.
• Directly held common shares totaled 40,513 following transactions.
• Directly held stock options totaled 53,288 following transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000047), on May 06, 2026, and is solely responsible for the information contained therein.